He has served as a member of our board of directors since December 2018 and Chairman of the Castle Audit Committee since May 2019. From November 2019 until April 2020, Mr. Cole served as General Manager, Precision Oncology, a unit of Exact Sciences Corporation, a molecular diagnostics company, following Exact Science Corporation s acquisition of Genomic Health, Inc. From June 2004 to November 2019, Mr. Cole served as Chief Financial Officer of Genomic Health, Inc., a publicly traded global provider of genomic-based diagnostic tests, where he also served as Chief Operating Officer from January 2009 until March 2018. Mr. Cole previously held Chief Financial Officer positions at multiple publicly traded companies, including Applied Biosystems, Inc. Since July of 2020, Mr. Cole has served on the board of Kiniksa Pharmaceuticals (KNSA), a public pharmaceutical company, and is a member of the audit committee. Mr. Cole also is the Vice Chairman of the Board of Trustees of Biola University where he has served since 2002. Mr. Cole holds a B.S. degree in Business - Accounting from Biola University and an MBA from San Jose State University. Independent Director Age: 70 Director since: 2018 Committees: Audit Committee (Chair) Compensation Committee Our Nominating and Corporate Governance Committee and board of directors believe that Mr. Cole s extensive experience in finance and operations as a public company executive and knowledge of the diagnostics industry qualify him to serve on our board of directors.